tiprankstipranks
Trending News
More News >
Croda International PLC (GB:49GP)
LSE:49GP
UK Market

Croda International (49GP) AI Stock Analysis

Compare
5 Followers

Top Page

GB

Croda International

(LSE:49GP)

Rating:67Neutral
Price Target:
97.00p
▲(10.86%Upside)
Croda International's overall stock score is driven by stable financial performance and a positive earnings call outlook, despite technical signals indicating potential overbought conditions. The absence of P/E ratio and dividend yield data complicates valuation assessment, but the company's strategic positioning and operational improvements provide a supportive backdrop for future growth.

Croda International (49GP) vs. iShares MSCI United Kingdom ETF (EWC)

Croda International Business Overview & Revenue Model

Company DescriptionCroda International Plc is a global specialty chemicals company that focuses on developing, manufacturing, and selling high-performance ingredients and technologies. It operates across various sectors including personal care, life sciences, and performance technologies. Croda is renowned for its innovation in sustainable solutions, offering a diverse range of products that improve everyday applications such as cosmetics, healthcare products, and industrial applications.
How the Company Makes MoneyCroda International generates revenue primarily through the sale of its specialty chemical products. The company's key revenue streams include its personal care segment, where it supplies ingredients for cosmetics and skincare products; life sciences, which covers pharmaceutical and healthcare applications; and performance technologies, which includes products for industrial applications like lubricants and coatings. Croda's earnings are bolstered by its commitment to sustainability and innovation, which drive customer demand for eco-friendly and efficient solutions. Additionally, strategic partnerships and collaborations with major companies in various industries contribute to its financial performance, as well as its investment in research and development to continually enhance its product offerings.

Croda International Earnings Call Summary

Earnings Call Date:Feb 25, 2025
(Q4-2024)
|
% Change Since: 1.07%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with notable achievements in Consumer Care and cash flow, but challenges in sales decline and price/mix headwinds were evident. The positive start to 2025 and strategic investments provide a cautiously optimistic outlook.
Q4-2024 Updates
Positive Updates
Consumer Care Growth
Consumer Care sales grew by 7% in constant currency, with local and regional customer sales up by 11%, driven by strong demand and innovation.
Operating Margin Improvement
Operating margin improved from 16.6% in the first half to 17.7% in the second half, aided by higher sales volumes and cost control measures.
Strong Cash Flow
Free cash flow increased to £181 million, up over 9%, with strong working capital discipline and reduced capital expenditure.
Positive Start to 2025
2025 began with good revenue growth across all businesses and markets, indicating a positive outlook.
Pharma Investment
Continued strategic investments in pharma, including new facilities in the US and Europe, positioning for future growth.
Negative Updates
Sales Decline
Group sales declined by 4% on a reported basis, with a significant 6% decline in Life Sciences sales.
Price/Mix Headwinds
Negative price/mix impact of 5.5% on sales, driven by raw material cost deflation and price adjustments.
Challenges in Life Sciences
Life Sciences faced challenges with a 6% sales decline, although there was a recovery in the second half.
Company Guidance
During the call, Croda provided guidance on its fiscal year 2024 performance, highlighting several key metrics. Group sales were reported at £1.6 billion, declining by 4% on a reported basis or 1% at constant currency. Adjusted operating profit decreased by 13% to £280 million. Profit before tax (PBT) was within the guidance range at £273 million or £260 million on a reported basis. The company maintained a strong cash flow with free cash flow up over 9% to £181 million. Divisional performance varied, with Consumer Care sales up 7% in constant currency and Industrial Specialties up 2%, while Life Sciences sales declined by 6%. Croda expects 2025 to start well with good revenue growth, anticipating Consumer Care and Life Sciences to grow, while Industrial Specialties remains flat. For 2025, the company projects group adjusted PBT to be between £265 million and £295 million at constant currency.

Croda International Financial Statement Overview

Summary
Croda International demonstrates a stable financial position with strong margins and a conservative balance sheet. The company maintains healthy cash flow generation relative to net income, although declining revenue and net profit margins indicate challenges in sustaining growth. The balance sheet's solid equity ratio and low leverage are positive indicators of financial health.
Income Statement
65
Positive
Croda International has experienced declining revenue over the past two years, with a 3.92% decrease from 2022 to 2023 and a further 3.92% decrease into 2024. The gross profit margin for 2024 stands at 45.08%, indicating strong control over cost of goods sold. However, the net profit margin has declined to 9.73% from 10.09% in 2023, reflecting challenges in maintaining profitability. The EBIT margin for 2024 is 13.97%, a decrease from 14.60% in 2023, while the EBITDA margin is 22.99%, down from 22.93% in 2023. The company shows resilience in maintaining decent margins despite revenue pressures.
Balance Sheet
75
Positive
The company's balance sheet reflects stability with a debt-to-equity ratio of 0.31 in 2024, showing a conservative leverage position. The return on equity (ROE) is 6.94%, down from 7.27% in 2023, suggesting a slight decline in efficiency at generating profits from equity. Croda's equity ratio stands at 65.03%, indicating a robust equity position relative to total assets, which is a positive indicator of financial health.
Cash Flow
70
Positive
Free cash flow decreased by 12.23% from 2023 to 2024, reflecting challenges in cash generation. The operating cash flow to net income ratio is 2.01, showing strong cash flow generation relative to net income. The free cash flow to net income ratio is 0.87, indicating a healthy conversion of net income into free cash flow. While cash flow metrics show strength in terms of cash generation, the decline in free cash flow growth highlights potential pressure on liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.63B1.69B2.09B1.89B1.39B
Gross Profit733.90M730.00M864.90M825.60M550.30M
EBITDA374.50M388.50M924.80M549.40M369.60M
Net Income158.50M171.00M649.30M320.80M201.60M
Balance Sheet
Total Assets3.51B3.58B3.61B3.29B3.03B
Cash, Cash Equivalents and Short-Term Investments166.80M172.50M320.60M112.80M106.50M
Total Debt699.10M710.10M615.80M936.00M907.00M
Total Liabilities1.21B1.21B1.18B1.53B1.43B
Stockholders Equity2.28B2.35B2.42B1.75B1.59B
Cash Flow
Free Cash Flow137.60M156.80M160.90M190.50M166.30M
Operating Cash Flow319.40M337.50M313.30M349.20M287.50M
Investing Cash Flow-139.10M-409.80M418.10M-218.40M-992.40M
Financing Cash Flow-182.60M-52.40M-550.90M-111.90M722.40M

Croda International Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price87.50
Price Trends
50DMA
85.97
Positive
100DMA
85.27
Positive
200DMA
85.49
Positive
Market Momentum
MACD
0.50
Positive
RSI
42.49
Neutral
STOCH
18.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:49GP, the sentiment is Neutral. The current price of 87.5 is below the 20-day moving average (MA) of 89.30, above the 50-day MA of 85.97, and above the 200-day MA of 85.49, indicating a neutral trend. The MACD of 0.50 indicates Positive momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 18.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:49GP.

Croda International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
GBVCT
70
Outperform
£678.41M22.846.65%7.64%4.75%-3.29%
GBTET
69
Neutral
£152.69M14.048.02%4.49%1.12%-0.70%
68
Neutral
£2.99B8.4315.96%4.58%-15.51%200.70%
67
Neutral
£4.15B
5.61%
GBELM
63
Neutral
£943.33M-5.93%1.57%0.71%-274.39%
57
Neutral
£2.64B4.88-9.97%4.27%-1.19%-6.71%
47
Neutral
£152.11M-6.25%0.81%15.63%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:49GP
Croda International
87.50
8.68
11.01%
GB:SYNT
Synthomer
97.40
-190.60
-66.18%
GB:VCT
Victrex
784.00
-297.23
-27.49%
GB:TET
Treatt plc
259.00
-170.43
-39.69%
GB:ELM
Elementis
164.00
21.45
15.05%
GB:JMAT
Johnson Matthey
1,804.00
255.27
16.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 04, 2025